ArticleBMC cardiovascular disorders2026
Association of plasma ADMA, FABP4 levels, and AIP with increased cardiovascular disease risk in Graves' disease: an exploratory pilot study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGraves' disease is an autoimmune disorder characterized by hyperthyroidism and is often associated with diffuse goiter, Graves' ophthalmopathy, antithyroid peroxidase antibodies, TSH receptor antibodies, and high serum thyroxine (T4) and triiodothyronine (T3) levels. Hyperthyroidism causes changes in the cardiovascular system that can be explained by the direct effects of thyroid hormones on vascular smooth muscle cells and cardiomyocytes. On the one hand, heart rate, myocardial contractility, preload, blood volume, and tissue thermogenesis increase, while on the other hand, afterload and systemic vascular resistance decrease.
objectivesThe aim of this exploratory pilot study was to investigate cardiovascular disease risk in patients with Graves' disease by evaluating the relationship between thyroid hormone levels and plasma Asymmetric Dimethylarginine (ADMA), Fatty Acid-Binding Protein 4 (FABP4), Atherogenic Index of Plasma (AIP), and Castelli Risk Index (CRI).
methodsThis study was designed as a cross-sectional study between January 2023 and January 2024 at the Endocrinology and Metabolism Department of Adana City Training and Research Hospital. The study included 30 newly diagnosed patients with Graves' disease, aged 18-65 years, who were recruited from the clinic. The diagnosis was confirmed clinically, biochemically, and through sonographic evaluation. As a control group, 30 euthyroid individuals aged 18-65 years, without thyroid disease, cardiac disease, hypertension, diabetes, or impaired glucose tolerance were selected. Demographic data, including age and gender, were recorded, and Body Mass Index (BMI) was calculated. Blood samples were collected to measure routine parameters such as Thyroid-Stimulating Hormone (TSH), Free Triiodothyronine (fT3), Free Thyroxine (fT4), Thyroid Receptor Antibodies (TRAB), Glucose, Blood Urea Nitrogen (BUN), Creatinine, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP), HDL, LDL, Total Cholesterol, and Triglycerides. In addition, the levels of ADMA and FABP4 were analyzed. The Atherogenic Index of Plasma (AIP) and Castelli Risk Index (CRI) were calculated.
resultsFABP4 levels were significantly higher in patients compared with the control group (10.03 ± 1.63 vs. 8.99 ± 1.24, p = 0.009). ADMA was significantly correlated with BMI (r = 0.402, p = 0.019), CRP (r = 0.479, p = 0.001), BUN (r = 0.462, p = 0.003), LDL (r = 0.443, p = 0.012), Total Cholesterol (r = 0.508, p = 0.004), and fT4 (r = 0.455, p = 0.005). Notably, ADMA had a strong positive correlation with FABP4 (r = 0.531, p < 0.001), CRI (r = 0.622, p < 0.001), and AIP (r = 0.642, p < 0.001). FABP4 was positively correlated with BMI (r = 0.514, p = 0.002), glucose (r = 0.577, p < 0.001), and TG (r = 0.614, p < 0.001). CRI was positively correlated with gender (Male) (r = 0.548, p = 0.003), BMI (r = 0.621, p < 0.001), glucose (r = 0.578, p < 0.001), and triglycerides (r = 0.949, p < 0.001). AIP showed a strong positive correlation with TG (r = 0.949, p < 0.001), BMI (r = 0.612, p < 0.001), Glucose (r = 0.576, p < 0.001), and Gender (Male) (r = 0.548, p = 0.003). ADMA demonstrated low discriminatory performance AUC of 0.614, with a cut-off value of > 132.9. It had a sensitivity and specificity of 75%, but the p-value was not significant (p = 0.145). FABP4 had a cut-off of > 8.47, with a sensitivity of 86% and specificity of 68% (AUC: 0.690, 95% CI: 0.551-0.829, p = 0.015). CRI had a cut-off value of > 3.27, with a sensitivity of 60% and specificity of 79% (AUC: 0.726, 95% CI: 0.620-0.832, p = 0.001). AIP showed a cut-off value of > 0.66, with sensitivity of 59% and specificity of 73% (AUC: 0.695, 95% CI: 0.587-0.803, p = 0.001).
conclusionThe findings suggest that biomarkers like FABP4, AIP, and CRI may provide insights into cardiovascular risk assessment in Graves' disease. However, further studies with larger cohorts are needed to validate these associations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.